Navigation Links
Uses and Applications of X-tremeGENE Q2 Transfection Reagent

Despite the wide spectrum of cell types that can be transfected using currently available transfection reagents, there are significant differences in the efficiency of DNA delivery into different types of cell. In certain cell types, such as HeLa, K-562, and Jurkat, the broad-spectrum transfection reagents available today usually provide relatively low transfection efficiency and low-level protein expression. The X-tremeGENE Q2 Transfection Reagent (X-Q2 Reagent) from Roche Applied Science was specially designed and optimized for high-efficiency gene delivery and high-level protein expression in HeLa, K-562, and Jurkat cells.

X-tremeGENE Q2 Transfection Reagent provides exceptional transfection efficiency in K-562 cells; approximately 20 - 30% of cells are transfected (Figure 1).



Figure 1: K-562 cells transfected with the X-tremeGENE Q2 Transfection Reagent and the X-tremeGENE pM1-beta-Gal vector (Roche Applied Science) show strong beta-galactosidase staining. Cells were plated in a 24-well plate (1 X 105 /well) and transfected with a complex of plasmid DNA (2 g) and X-tremeGENE Q2 Transfection Reagent (4 l). 48 hours post transfection, cells were stained for beta-Gal expression using the beta-Gal Staining Set from Roche Applied Science, Cat. No. 1 828 673.

The level of beta-galactosidase (beta-Gal) expression within each K-562 cell can vary as seen here from intense blue to light blue. The level of beta-Gal expression obtained with the X-tremeGENE Q2 Transfection Reagent was several-fold higher than the next best competitor reagent recommended for the transfection of K-562 cells (data not shown), even when the same vector was used under optimized conditions for both reagents.

In Jurkat cells , the X-tremeGENE Q2 Transfection Reagent also produced beta-Gal expression that was several-fold higher than competitor reagents L-2 and DC (Figure 2). In these experiments, the X-tremeGENE pM1-beta-Gal vector was used with each transfection reagent (in other experiments, the ratios of DNA to transfection reagents and the total amount of complex added per cell were optimized for each reagent)

.

Figure 2: Jurkat cells transfected with the X-tremeGENE Q2 Transfection Reagent showed higher levels of beta-Gal expression than currently recommended competitor reagents L-2 or DC. Cells (4x105/ well) were transfected with the X-tremeGENE pM1-beta-Gal vector (Roche Applied Science) in a 24-well plate. In each case, the ratios of DNA / transfection reagent and the amount of complex used in each well following optimization were those recommended by the suppliers. The level of reporter gene expression was determined 48 hours post transfection, using the beta-Gal Reporter Gene Assay Kit (Roche Applied Science, Cat. No. 1 758 241).

Note: The level of expression of a transfected gene will vary with the specific cell type, number of cells transfected, quantity of plasmid DNA used, ratio of transfection reagent to DNA, type of expression vector, cell culture medium, and the culture conditions.


'"/>

Source:


Page: All 1 2

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Highest Possible Transformation Efficiencies for High-Throughput Applications
3. Unique DNA Polymerase Formulation Excels in a Broad Range of PCR Applications
4. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
5. Optimizing Büchi® Rotary Evaporator Applications
6. Optimizing Büchi® Rotary Evaporator Applications
7. Optimizing Bchi Rotary Evaporator Applications
8. Uses and Applications of FuGENE 6 Transfection Reagent
9. Uses and Applications of FuGENE 6 Transfection Reagent
10. Uses and Applications of FuGENE 6 Transfection Reagent
11. Uses and Applications of FuGENE 6 Transfection Reagent
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... SAN DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: ... year ended December 31, 2015. --> ... reported a net loss of $29.3 million, or $0.34 loss per ... loss per share for the same period in 2014. For the ... of $88.9 million, or $1.05 loss per share, as compared to ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... York, NY (PRWEB) , ... ... ... (BPI), a business-to-business publication dedicated to delivering cutting-edge information focused on the ... Healthcare Life Sciences to become a premier sponsor of the 2016 BioProcess ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):